About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.

Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Clinicaltrials.gov identifier NCT03935074

Recruitment Status Completed

First Posted May 2, 2019

Last update posted May 6, 2019

Study Description

Brief summary:

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

  • Condition or Disease:Retinoblastoma
  • Intervention/Treatment: Drug: intra-arterial administration of melphalan
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Actual Enrollment: 30 participants
  • Observational Model: Case-Only
  • Time Perspective: Retrospective
  • Official Title: Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
  • Actual Study Start Date: August 2016
  • Actual Primary Completion Date: November 2016
  • Actual Study Completion Date: November 2016
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: group 1
Patients who received intra-arterial chemotherapy as a first line treatment
Drug: intra-arterial administration of melphalan
: group 2
Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
Drug: intra-arterial administration of melphalan
Outcome Measures
  • Primary Outcome Measures: 1. globe salvage [ Time Frame: 2-5 years ]
    globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma
Eligibility Criteria
  • Ages Eligible for Study: 5 to 7 Months (Child)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers:
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients diagnosed with retinoblastoma and who received superselective intra-arterial chemotherapy as a first line treatment or as a salvage treatment after systemic chemotherapy
Criteria

Inclusion Criteria:

- patients diagnosed with unilateral/bilateral retinoblastoma

Exclusion Criteria:

- patients with trilateral retinoblastoma

- extraoculer involvement

- patients with blood dyscrasias, bleeding and clotting disorders

Contacts and Locations
Contacts
Locations

Turkey
Istanbul University Cerrahpasa School of Medicine Ophthalmology Department
Istanbul

Sponsors and Collaborators

Istanbul University-Cerrahpasa

More Information